BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 28216163)

  • 1. IL-33 facilitates endocrine resistance of breast cancer by inducing cancer stem cell properties.
    Hu H; Sun J; Wang C; Bu X; Liu X; Mao Y; Wang H
    Biochem Biophys Res Commun; 2017 Apr; 485(3):643-650. PubMed ID: 28216163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells.
    Choi EJ; Seo EJ; Kim DK; Lee SI; Kwon YW; Jang IH; Kim KH; Suh DS; Kim JH
    Oncotarget; 2016 Jan; 7(3):3506-19. PubMed ID: 26654944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of embryonal stem cell transcription factors in breast cancer: Oct4 as an indicator for poor clinical outcome and tamoxifen resistance.
    Gwak JM; Kim M; Kim HJ; Jang MH; Park SY
    Oncotarget; 2017 May; 8(22):36305-36318. PubMed ID: 28422735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
    Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
    Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sox2 promotes tamoxifen resistance in breast cancer cells.
    Piva M; Domenici G; Iriondo O; Rábano M; Simões BM; Comaills V; Barredo I; López-Ruiz JA; Zabalza I; Kypta R; Vivanco Md
    EMBO Mol Med; 2014 Jan; 6(1):66-79. PubMed ID: 24178749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic interaction between ER and HMGB2 identifies DDX18 as a novel driver of endocrine resistance in breast cancer cells.
    Redmond AM; Byrne C; Bane FT; Brown GD; Tibbitts P; O'Brien K; Hill AD; Carroll JS; Young LS
    Oncogene; 2015 Jul; 34(29):3871-80. PubMed ID: 25284587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells.
    Yin Y; Xie CM; Li H; Tan M; Chen G; Schiff R; Xiong X; Sun Y
    Proc Natl Acad Sci U S A; 2019 Oct; 116(41):20528-20538. PubMed ID: 31548378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer.
    Santiago-Gómez A; Kedward T; Simões BM; Dragoni I; NicAmhlaoibh R; Trivier E; Sabin V; Gee JM; Sims AH; Howell SJ; Clarke RB
    Cancer Lett; 2019 Aug; 458():66-75. PubMed ID: 31121213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Cellular Transforming Activity of OCT4, NANOG, and SOX2 in Immortalized Astrocytes.
    Seo S; Jeon HY; Kim H
    DNA Cell Biol; 2017 Nov; 36(11):1000-1009. PubMed ID: 28933914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-484 suppresses endocrine therapy-resistant cells by inhibiting KLF4-induced cancer stem cells in estrogen receptor-positive cancers.
    Wei Y; Li H; Qu Q
    Breast Cancer; 2021 Jan; 28(1):175-186. PubMed ID: 32865695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ.
    Lü M; Ding K; Zhang G; Yin M; Yao G; Tian H; Lian J; Liu L; Liang M; Zhu T; Sun F
    Sci Rep; 2015 Mar; 5():8735. PubMed ID: 25736597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity.
    Simões BM; O'Brien CS; Eyre R; Silva A; Yu L; Sarmiento-Castro A; Alférez DG; Spence K; Santiago-Gómez A; Chemi F; Acar A; Gandhi A; Howell A; Brennan K; Rydén L; Catalano S; Andó S; Gee J; Ucar A; Sims AH; Marangoni E; Farnie G; Landberg G; Howell SJ; Clarke RB
    Cell Rep; 2015 Sep; 12(12):1968-77. PubMed ID: 26387946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
    Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
    J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance.
    Takahashi M; Hayashida T; Okazaki H; Miyao K; Jinno H; Kitagawa Y
    Cancer Sci; 2014 Jun; 105(6):675-82. PubMed ID: 24698107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP.
    Piggott L; Silva A; Robinson T; Santiago-Gómez A; Simões BM; Becker M; Fichtner I; Andera L; Young P; Morris C; Barrett-Lee P; Alchami F; Piva M; Vivanco MD; Clarke RB; Gee J; Clarkson R
    Clin Cancer Res; 2018 May; 24(10):2452-2463. PubMed ID: 29363524
    [No Abstract]   [Full Text] [Related]  

  • 16. GSKJ4, an H3K27me3 demethylase inhibitor, effectively suppresses the breast cancer stem cells.
    Yan N; Xu L; Wu X; Zhang L; Fei X; Cao Y; Zhang F
    Exp Cell Res; 2017 Oct; 359(2):405-414. PubMed ID: 28823831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells.
    Bergamaschi A; Madak-Erdogan Z; Kim YJ; Choi YL; Lu H; Katzenellenbogen BS
    Breast Cancer Res; 2014 Sep; 16(5):436. PubMed ID: 25213081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
    Giannoudis A; Malki MI; Rudraraju B; Mohhamed H; Menon S; Liloglou T; Ali S; Carroll JS; Palmieri C
    Breast Cancer Res; 2020 Nov; 22(1):126. PubMed ID: 33198803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties.
    Lin X; Li J; Yin G; Zhao Q; Elias D; Lykkesfeldt AE; Stenvang J; Brünner N; Wang J; Yang H; Bolund L; Ditzel HJ
    Breast Cancer Res; 2013 Dec; 15(6):R119. PubMed ID: 24355041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [LincRNA-ROR functions as a ceRNA to regulate Oct4, Sox2, and Nanog expression by sponging miR-145 and its effect on biologic characteristics of colonic cancer stem cells].
    Yan ZY; Sun XC
    Zhonghua Bing Li Xue Za Zhi; 2018 Apr; 47(4):284-290. PubMed ID: 29690669
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.